Section 174 R&D capitalization for tech and life science companies
The House’s draft tax revision bill proposes temporary relief from Section 174 R&D capitalization rules, allowing life sciences and technology companies to immediately expense domestic R&D costs from 2025 to 2029. This change offers strategic tax planning opportunities and reduces compliance burdens for innovation-driven companies.
Images
Additional Info
Media Contact : Courtney Boyd
Related Links : https://www.cohnreznick.com/insights/draft-tax-bill-eases-r-d-burden-tech-life-sciences
Powered By GrowthZone